Processing your request


please wait...

Case Page

 

Case Status:    DISMISSED    
On or around 10/19/2017 (Stipulation and order of dismissal (voluntary dismissal))

Filing Date: February 17, 2017

Alcobra Ltd. is a pharmaceutical company that has been focused on the development and commercialization of new medications for CNS disorders including ADHD and Fragile X Syndrome.

According to the law firm press release, the Complaint alleges that Defendants caused the Company to issue materially misleading statements and/or omit material information concerning the Company's second Phase III study for MDX in adults with ADHD, the "MDX Evaluation in Adults – Study of Response and Efficacy," or the "MEASURE" study. The Complaint alleges these misstatements and omissions by Alcobra violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On July 21, 2017, the Court appointed Lead Plaintiffs and Counsel.

On October 19, 2017, this case was voluntarily dismissed pursuant to a Stipulation by the parties.

Protected Content


Please Log In or Sign Up for a free account to access restricted features of the Clearinghouse website, including the Advanced Search form and the full case pages.

When you sign up, you will have the option to save your search queries performed on the Advanced Search form.